Drug
Ubamatamab
Ubamatamab: highest development phase Phase 2, developed by Regeneron. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ubamatamab NCT06787612 | Phase 2 | Ovarian Cancer |
| Ubamatamab NCT06444880 | Phase 2 | SMARCB1-Deficient Malignancies |
| Ubamatamab NCT03564340 | Phase 1/2 | Recurrent Ovarian Cancer |
| Ubamatamab NCT07637851 | Phase 1/2 | Ovarian Cancer |
Latest
No recent events.
Follow Ubamatamab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.